Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.55 |
| ▸ | ITGAV | P06756 | 20/20 | 0.55 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21282945 | 0.96 | ITGB3 (0.57) | ITGB3ITGAVITGB5 | |
| SCHEMBL29744197 | 0.93 | ITGB3 (0.64) | ITGB3ITGAVITGB5 | |
| SCHEMBL20139279 | 0.93 | ITGB3 (0.64) | ITGB3ITGAVITGB5 | |
| SCHEMBL20139278 | 0.93 | ITGB3 (0.64) | ITGB3ITGAVITGB5 | |
| SCHEMBL29744119 | 0.93 | ITGB3 (0.64) | ITGB3ITGAVITGB5 | |
| SCHEMBL20139766 | 0.93 | ITGB3 (0.64) | ITGB3ITGAVITGB5 | |
| SCHEMBL29744070 | 0.93 | ITGB3 (0.64) | ITGB3ITGAVITGB5 | |
| SCHEMBL20153818 | 0.90 | ITGB3 (0.51) | ITGB3ITGAVITGB5 | |
| SCHEMBL21282943 | 0.89 | ITGB3 (0.59) | ITGB3ITGAVITGB5 | |
| SCHEMBL20141067 | 0.88 | ITGB3 (0.63) | ITGB3ITGAVITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | ITGB3 3/4885ITGAV 1/4885ITGB5 4/4885 |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | ITGB3 3/4885ITGAV 1/4885ITGB5 4/4885 |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | ITGB3, ITGB1, ITGAV | ITGB3 1/4885ITGAV 3/4885ITGB5 5/4885 |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | ITGAV, ITGB1, ITGB3 | ITGB3 3/4885ITGAV 1/4885ITGB5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.